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Abstract
Background: The safety, tolerability, and immunogenicity of a monovalent intranasal 2009 A/H1N1 live attenuated influenza
vaccine (LAIV) were evaluated in children and adults.
Methods/Principal Findings: Two randomized, double-blind, placebo-controlled studies were completed in children (2–17
y) and adults (18–49 y). Subjects were assigned 4:1 to receive 2 doses of H1N1 LAIV or placebo 28 days apart. The primary
safety endpoint was fever $38.3uC during days 1–8 after the first dose; the primary immunogenicity endpoint was the
proportion of subjects experiencing a postdose seroresponse. Solicited symptoms and adverse events were recorded for 14
days after each dose and safety data were collected for 180 days post-final dose. In total, 326 children (H1N1 LAIV, n=261;
placebo, n=65) and 300 adults (H1N1 LAIV, n=240; placebo, n=60) were enrolled. After dose 1, fever $38.3uC occurred in
4 (1.5%) pediatric vaccine recipients and 1 (1.5%) placebo recipient (rate difference, 0%; 95% CI: –6.4%, 3.1%). No adults
experienced fever following dose 1. Seroresponse rates in children (H1N1 LAIV vs. placebo) were 11.1% vs. 6.3% after dose 1
(rate difference, 4.8%; 95% CI: –9.6%, 13.8%) and 32.0% vs. 14.5% after dose 2 (rate difference, 17.5%; 95% CI: 5.5%, 27.1%).
Seroresponse rates in adults were 6.1% vs. 0% (rate difference, 6.1%; 95% CI: –5.6%, 12.6%) and 14.9% vs. 5.6% (rate
difference, 9.3%; 95% CI: –0.8%, 16.3%) after dose 1 and dose 2, respectively. Solicited symptoms after dose 1 (H1N1 LAIV vs.
placebo) occurred in 37.5% vs. 32.3% of children and 41.7% vs. 31.7% of adults. Solicited symptoms occurred less frequently
after dose 2 in adults and children. No vaccine-related serious adverse events occurred.
Conclusions/Significance: In subjects aged 2 to 49 years, two doses of H1N1 LAIV have a safety and immunogenicity profile
similar to other previously studied and efficacious formulations of seasonal trivalent LAIV.
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Introduction
In response to the 2009 H1N1 influenza pandemic, MedIm-
mune (Gaithersburg, MD) developed a live attenuated intranasal
H1N1 vaccine based on the Ann Arbor 6:2 reassortant technology
used to produce the annual trivalent seasonal influenza vaccine
(MedImmune, Gaithersburg, MD) [1,2]. Live attenuated influenza
vaccines (LAIVs) are well suited to confront pandemic and
epidemic influenza and may confer distinct advantages compared
with inactivated or subunit vaccines [3]. Data from 3 large
placebo-controlled clinical studies indicate that relatively high
levels of efficacy (ranging from 60% to 90%) are seen in previously
unvaccinated young children after a single dose of trivalent LAIV.
Efficacy following a single dose of LAIV is an important
consideration for pandemic influenza; experiences with unadju-
vanted, inactivated seasonal and H5N1 influenza vaccines indicate
that two doses may be required in order to generate robust
immune responses to novel influenza strains in unprimed
individuals such as young children [4–6]. However, fewer than
25% of children 2 to 8 years of age who are recommended to
receive two doses of seasonal influenza vaccines actually receive
both doses [7]. LAIV has also demonstrated protection against
influenza strains in children and adults that are antigenically
distinct from those contained in the vaccine [8–11]. At the onset of
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considered a useful attribute of the vaccine as it was not known to
what extent circulating strains of H1N1 might antigenically drift
from the vaccine strain over time. LAIV may also induce an innate
antiviral state that results in protection from influenza during the
days immediately after vaccination; this would clearly be relevant
if high levels of influenza transmission were already present when
the vaccine became available [12,13]. Due to manufacturing
capacity advantages, LAIVs may also be the preferred technology
to address a pandemic [14]. Finally, administration of LAIV is
rapid, needle-free, and avoids issues associated with blood
exposure and use of sharps, and is thus well suited to mass
vaccination campaigns in community settings such as schools
[15–17].
The objective of the clinical studies was to evaluate the safety,
tolerability, and immunogenicity of 2 doses of a monovalent
intranasal A/H1N1 LAIV administered 28 days apart in children
and adults prior to U.S. licensure and subsequent widespread
distribution of the vaccine. Interim results were provided to the US
Food and Drug Administration (FDA) as they became available;
this report provides the complete long-term safety and immuno-
genicity data for the 2 studies.
Methods
Full trial protocols of the two studies and the CONSORT
checklist for this report are available as supporting information; see
Protocol S1, Protocol S2, and Checklist S1, respectively.
Ethics
Individual participants or their parents/legal representatives
gave written informed consent. Pediatric assent was also obtained,
if appropriate. The study protocol and consent/assent forms were
approved by the Copernicus Group Institutional Review Board,
Research Triangle Park, NC.
Study Design
Two randomized, double-blind, placebo-controlled studies were
conducted at multiple sites in the United States to evaluate the
safety and immunogenicity of 2 doses of H1N1 LAIV in healthy
children aged 2 to 17 years (Clinicaltrials.gov identifier,
NCT00946101) and healthy adults aged 18 to 49 years
(Clinicaltrials.gov identifier, NCT00945893). The design of the
studies was modeled on studies that have been conducted annually
in the United States to evaluate the attenuation of LAIV strains
expressing updated hemagglutinin (HA) and neuraminidase (NA)
antigens before their incorporation into trivalent seasonal LAIV
formulations (e.g., Clinicaltrials.gov identifier, NCT00873912).
Eligible subjects were randomly assigned using an interactive voice
response system in a 4:1 ratio to receive 2 doses of live monovalent
H1N1 LAIV or placebo by intranasal spray 28 days apart (i.e., on
days 1 and 29). In the adult study, randomization was stratified by
site. In the pediatric study, randomization was stratified by age (2–
8 y and 9–17 y). Subjects in both studies were further randomized
(1:1) to provide a blood sample on either day 15 or day 29 after
their first vaccination. A final immunogenicity blood sample was
collected on day 57, approximately 28 days after the second
vaccination. After the blinded portion of the study was concluded,
subjects randomized to receive placebo in the studies were offered
optional H1N1 vaccination after collection of their Day 57 blood
sample. The studies were conducted in compliance with the
International Conference on Harmonisation Guidelines for Good
Clinical Practice and the Declaration of Helsinki.
Vaccine
The 2009 H1N1 LAIV was produced by MedImmune and was
derived by genetic reassortment of the hemagglutinin and
neuraminidase genes from the wild-type A/California/7/2009
virus and the remaining 6 gene segments from an attenuated
master donor virus as previously described [1,2,18]. The resulting
6:2 reassortant vaccine virus is a temperature-sensitive, cold-
adapted, attenuated virus that is grown in chicken eggs using the
same manufacturing process used to produce MedImmune’s
seasonal trivalent LAIV. Monovalent vaccine was supplied in
intranasal spray applicators containing approximately 10
7 fluores-
cent focus units (FFU) of the reassortant influenza virus in a total
volume of 0.5 mL of sucrose-phosphate buffer and egg allantoic
fluid (0.25 mL administered into each nostril). Placebo (0.5 mL of
sucrose-phosphate buffer) was supplied and administered using
identical intranasal applicators.
Subjects
Exclusion criteria included hypersensitivity to any component of
the vaccine or placebo; medical conditions that predispose to
complications from influenza (e.g. lung disease, heart disease, renal
disease, metabolic disease such as diabetes); acute febrile and/or
clinically significant respiratory illness within 14 days of randomiza-
tion; history of asthma, recurrent wheezing (in children ,5y e a r so f
age), or history of Guillain-Barre ´s y n d r o m e ;o ra n yk n o w n
immunosuppressive condition or immune deficiency disease. All
women of child-bearing potential were required to have a negative
pregnancy test at screening and immediately before each vaccination.
Complete eligibility criteria are described in Supporting Text S1.
Safety Assessments
The primary safety analysis compared the rates of fever during
days 1 to 8 after dose 1. Fever was defined as a temperature
$38.3uC (101uF). Additional safety endpoints included solicited
symptoms, adverse events (AEs), and antipyretic and analgesic use
from day 1 through day 8 and from day 1 through day 15 after
each vaccination. Serious adverse events (SAEs) and new onset
chronic diseases (NOCDs) were collected through 180 days after
the final dose. Memory aid worksheets were provided to record
solicited symptoms, AEs, and concomitant medication use for 14
days after dosing. Solicited symptoms, reported as present or
absent, included fever (temperature was recorded daily), runny
nose (adults) or runny/stuffy nose (children), sore throat, cough,
vomiting (adults), muscle aches, chills (adults), decreased activity,
decreased appetite (children), and headache. Antipyretic and/or
analgesic use was discouraged during the 14 days postvaccination
to avoid masking the primary safety endpoint of fever. Subjects
who experienced a febrile illness within 7 days after dose 1 were
instructed to return to the study site for evaluation.
Laboratory Assays
To assess humoral responses to the vaccine, serum antibody
titers were measured at randomization (baseline) and on day 15 or
29 after dose 1 and on day 57 (28 days after dose 2) using a
standardized hemagglutination inhibition (HAI) assay against
antigenically matched influenza A/H1N1 6:2 virus reassortants,
performed as previously described [19]. Full details are provided
in Supporting Text S2.
Statistical Analyses
Sample size and power calculations were based on the primary
safety endpoint. A sample size of 300 was estimated to provide at
least 80% power to detect a 10 percentage point difference in the
2009 Intranasal H1N1 Vaccine
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the true fever rate in the vaccine group was less than 8%. The
same sample size (n=300) was estimated to provide at least 99%
power to rule out a fever rate difference of 10 percentage points in
adults if the true difference was 0% and the true fever rate in the
vaccine group was less than 3%. A 2-sided 95% exact confidence
interval (CI) for the rate difference (vaccine minus placebo) was
calculated based on score statistics proposed by Chan and Zhang
[20] and the upper limit of the CI was evaluated against a pre-
specified equivalence criteria of 10%. Rate differences and the
exact 2-sided 95% CIs for the rate differences were also calculated
for other reported solicited symptoms between the two treatment
groups; there were no pre-specified equivalence criteria for these
secondary analyses. The incidence of AEs and the proportion of
subjects using antipyretics and/or analgesics on days 1 to 8 and
days 1 to 15 after doses 1 and 2 were also summarized.
The primary immunogenicity endpoint was the proportion of
subjects experiencing a postvaccination seroresponse in baseline
seronegative subjects and in all subjects regardless of baseline
serostatus. Seroresponse was defined as a $4-fold rise in HAI titer
from baseline. Subjects with baseline HAI titers of #4 were
considered seronegative. Secondary immunogenicity endpoints
were the proportion of subjects with a postdose HAI titer $32 and
HAI geometric mean titers (GMTs). Two-sided exact 95% CIs
were constructed for rate differences using the exact method
proposed by Chan and Zhang [20]. Geometric mean titers
(GMTs) were calculated as GMT=anti-loge(mean[loge X1i]),
where X1i is the postdose assay result for subject i.
The intent-to-treat (ITT) population included all randomized
subjects based on treatment assignment. All subjects who received
at least 1 dose of study vaccine and had any safety follow-up
comprised the safety population. Subjects were considered part of
the post dose 1 immunogenicity population if they received dose 1
of the study vaccine and had valid HAI measurements from blood
samples obtained at baseline and post dose 1. Subjects were
considered part of the post dose 2 immunogenicity population if
they received 2 doses of the same study vaccine and had valid HAI
measurements from blood samples obtained at baseline and post
dose 2. Subjects with major protocol violations were not included
in the immunogenicity populations.
Results
Subjects
From August 17–19, 2009, a total of 326 children and 300
adults were randomized at a 4:1 ratio to receive H1N1 LAIV or
placebo (Figure 1). Demographic characteristics of the ITT
populations are summarized in Table 1. The mean ages for
children were 8.9 and 9.2 years for the HINI LAIV and placebo
groups, respectively and for adults were 33.3 and 34.1 years,
respectively. Of the 326 randomized children, 324 subjects
received dose 1 and were included in the safety analyses (H1N1
LAIV, n=259; placebo, n=65), and 319 subjects (H1N1 LAIV,
n=256, placebo, n=63) received dose 2. One child randomized
to receive H1N1 LAIV inadvertently received placebo at dose 1
and was included in the H1N1 LAIV group in the ITT
population, but was included among placebo recipients for dose
1 safety analyses. All 300 randomized adults received dose 1
(H1N1 LAIV, n=240; placebo, n=60), and 283 received dose 2
(H1N1 LAIV, n=228; placebo, n=55).
Safety Analyses
Safety data was collected from 324 children (H1N1 LAIV,
n=259; placebo, n=65) after dose 1 and 318 children (H1N1
LAIV, n=255; placebo, n=63) after dose 2, and from 300 adults
(H1N1 LAIV, n=240; placebo, n=60) after dose 1 and 283
adults (H1N1 LAIV, n=228; placebo, n=55) after dose 2. There
was no statistical difference between treatment groups for the
primary endpoint (fever $38.3uC for days 1–8 postdose 1) in
children or adults. Among children, fever $38.3uC occurred in
1.5% (n=4) of H1N1 LAIV and 1.5% (n=1) of placebo recipients
after dose 1 (rate difference, 0%; 95% CI: –6.4%, 3.1%) and 1.2%
(n=3) and 0% after dose 2 (rate difference, 1.2%; 95% CI: –4.1%,
3.7%). Fever was not reported among adult subjects after dose 1
but was reported in 0.4% (n=1) and 1.8% (n=1) of H1N1 LAIV
and placebo recipients after dose 2 (rate difference, –1.4%; 95%
CI: –8.7%, 1.4%). In both children and adults, antipyretic and/or
analgesic use following dose 1 and 2 was not significantly different
among H1N1 LAIV and placebo recipients (data not shown).
Solicited symptoms were collected in children and adults from
day 1 through day 15 after both doses. Data collected through day
Table 1. Demographics by Treatment Group (Intent-to-Treat
Population).
Children (2–17 y) Adults (18–49 y)
Baseline Characteristics
H1N1
LAIV Placebo
H1N1
LAIV Placebo
n 261 65 240 60
Age, y
Mean (SD) 8.9 (4.3) 9.2 (4.3) 33.3 (9.2) 34.1 (8.9)
Median 8.0 10.0 33.0 32.0
Minimum–maximum 2–17 2–17 18–49 18–49
Age group, n (%)
2–8 y 133 (51.0) 31 (47.7) NA NA
9–17 y 128 (49.0) 34 (52.3) NA NA
Gender, n (%)
Male 131 (50.2) 29 (44.6) 102 (42.5) 27 (45.0)
Female 130 (49.8) 36 (55.4) 138 (57.5) 33 (55.0)
Ethnicity, n (%)
Hispanic or Latino 50 (19.2) 17 (26.2) 95 (39.6) 18 (30.0)
Non–Hispanic or –Latino 211 (80.8) 48 (73.8) 145 (60.4) 42 (70.0)
Race, n (%)
American Indian or Alaskan
Native
4 (1.5) 0 (0.0) 1 (0.4) 0 (0.0)
Asian 2 (0.8) 4 (6.2) 0 (0.0) 0 (0.0)
Black or African American 43 (16.5) 12 (18.5) 37 (15.4) 13 (21.7)
Native Hawaiian or Pacific
Islander
2 (0.8) 0 (0.0) 1 (0.4) 0 (0.0)
White 198 (75.9) 43 (66.2) 199 (82.9) 47 (78.3)
Other 4 (1.5) 5 (7.7) 1 (0.4) 0 (0.0)
Multiracial 8 (3.1) 1 (1.5) 1 (0.4) 0 (0.0)
LAIV=live attenuated influenza vaccine; NA=not applicable.
doi:10.1371/journal.pone.0013755.t001
Figure 1. Subject Disposition (ITT Population): (A) Children and (B) Adults. ITT=intent to treat; LAIV=live attenuated influenza vaccine.
*One child randomized to receive H1N1 LAIV was inadvertently administered placebo for dose 1; this subject also received placebo for dose 2. This
subject was included in the H1N1 group for ITT analyses, but was grouped with placebo subjects for safety analyses.
doi:10.1371/journal.pone.0013755.g001
2009 Intranasal H1N1 Vaccine
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e137558 post dose 1 and dose 2 are presented in Figures 2 and 3 (data
through day 15 after each dose are presented in Supplemental
Figures S1 and S2). In general, H1N1 LAIV recipients reported
more solicited symptoms compared with placebo recipients.
Through day 8 after dose 1, 37.1% of children receiving H1N1
LAIV and 32.3% of placebo children reported at least one
solicited symptom (rate difference 4.8%; 95% CI: –8.%, 17.2%);
among adults, the percentages were 41.7% and 31.7%, respec-
tively (rate difference, 10.0%; 95% CI: –4.1%, 22.8%; Figure 2).
The percentage of individuals reporting solicited symptoms
decreased in both adults and children after dose 2 (Figure 3).
The most common solicited symptom in children receiving
H1N1 LAIV through day 8 post dose 1 was headache which was
reported by 16.6% and 15.4% of H1N1 LAIV and placebo
recipients, respectively (rate difference, 1.2%; 95% CI: –10.2%,
10.2%) The most common solicited symptom through day 8 post
dose 2 in children receiving H1N1 LAIV was runny/stuffy nose
(Figure 2). For children, the rate differences for all solicited
symptoms were not statistically significant between H1N1 LAIV
and placebo recipients.
In adults, the most common solicited symptom reported
through day 8 post dose 1 was headache which was reported by
Figure 2. Solicited Symptoms in (A) Children and (B) Adults Through Day 8 Postvaccination with Dose 1. *P,0.05.
doi:10.1371/journal.pone.0013755.g002
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respectively, after dose 1 and 11.8% and 16.4% through day 8
after dose 2. The rate of headaches in adults receiving H1N1
LAIV compared with placebo did not differ significantly. Through
day 8 after dose 1 significantly more adults who received H1N1
LAIV experienced runny nose (H1N1 LAIV, 15.4%; placebo
5.0% [rate difference, 10.4%; 95% CI: 1.2%,17.2%]) and muscle
aches (H1N1 LAIV, 6.7%; placebo, 0.0%; [rate difference, 6.7%;
95% CI: 0.8%,10.8%]). For adults receiving H1N1 LAIV the
incidence of solicited symptoms was lower through day 8 following
dose 2 and only muscle aches were significantly greater in H1N1
LAIV recipients. No other rate differences for solicited symptoms
in adults were significant.
Adverse events (AEs) were collected during days 1–15 after
doses 1 and 2 in children and adults. In children, AEs after dose 1
were reported in 18.1% and 16.9% of H1N1 LAIV and placebo
recipients, respectively, and in 13.7% and 14.3% of recipients after
dose 2 (Supplemental Table S1). The most common AEs in
children after dose 1 were nausea (1.9% vs 3.1%), vomiting (2.7%
vs 1.5%), and diarrhea (1.5% vs 1.5%). The overall frequency of
adverse events was lower following dose 2. Three SAEs were
reported in children during the study, hospitalization for
Figure 3. Solicited Symptoms in (A) Children and (B) Adults Through Day 8 Postvaccination with Dose 2. *P,0.05.
doi:10.1371/journal.pone.0013755.g003
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placebo recipient; all were considered unrelated to study vaccine.
One new onset chronic disease (NOCD), attention deficit
hyperactivity disorder, was reported in a placebo recipient.
In adults, AEs were reported by 15.8% of H1N1 LAIV
recipients and 16.7% of placebo recipients after dose 1 and 7.9%
and 7.3% after dose 2 (Supplemental Table S2). Generally,
more AEs were reported after dose 1 and the most common were
nausea (H1N1 LAIV, 2.1%; placebo, 3.3%), nasal congestion
(1.7% vs 1.7%), and sneezing (1.7% vs 3.3%). Four SAEs were
reported during the study in adults for cellulitis and depression in
vaccine recipients, gallbladder disease and possible cervical cancer
in placebo recipients; all were considered unrelated to study
vaccine. Two NOCDs, hypothyroidism in a vaccine recipient and
possible cervical cancer in a placebo recipient were reported and
not considered to be treatment-related. One adult subject who
received H1N1 LAIV was diagnosed with A/H1N1 influenza 13
days after dose 1 and was discontinued from the study.
Immunogenicity
Serum for HAI antibody titer analysis was collected at baseline,
on day 15 or 29 after dose 1 and on day 57 (28 days after dose 2) in
both children and adults. The proportions of H1N1 LAIV and
placebo recipients who were seronegative at baseline were
comparable for children and adults (children: H1N1 LAIV,
88.6%; placebo, 90.6%; adults: H1N1 LAIV, 85.1%; placebo,
76.3%). Among all children regardless of baseline serostatus,
seroconversion rates after vaccination with H1N1 LAIV were
7.8% and 11.1% for study days 15 and 29, respectively, and
32.0% on day 57. For placebo recipients, seroconversion rates
were 6.3% on days 15 and 29, and 14.5% on day 57 (Table 2).
For the subset of all children 2 to 9 years of age (regardless of
baseline serostatus) who are recommended to receive two doses of
the H1N1 vaccine [21] seroconversion rates were similar; 8.5%,
15.1% and 28.0% for vaccine recipients and 0%, 0% and 6.7% for
placebo recipients on days 15, 29 and 57, respectively (Table 2).
Among adults regardless of baseline serostatus, seroconversion
rates after H1N1 LAIV were 2.5% and 6.1% for days 15 and 29,
respectively, and 14.9% on day 57. For adult placebo recipients
regardless of baseline serostatus, seroconversion rates were 0% on
day 15 and 29 and 5.6% on day 57 (Table 3). Seroconversion
rates were slightly higher among adult subjects who were
seronegative at baseline.
Discussion
The 2009 H1N1 LAIV vaccine, administered as 2 doses 28 days
apart, has a reassuring safety profile and is well tolerated in
children and adults. The local and systemic symptoms observed in
these studies are consistent with intranasal viral replication, are
comparable to what has been observed in previous studies with
seasonal LAIV, and demonstrate that this H1N1 LAIV strain is
appropriately attenuated. The overall safety profile of the vaccine
is consistent with that reported for other seasonal LAIV vaccines
[10,22–26], which is expected since these vaccines are generated
from the same master donor virus responsible for conferring
attenuation, cold-adaptation and temperature sensitivity [27].
While the number of subjects enrolled in these studies would not
have allowed for the detection of rare safety signals, the overall
safety of the vaccine is supported by post-marketing surveillance
data [28]. The U.S. Centers for Disease Control and Prevention
analyzed adverse events received through the Vaccine Adverse
Event Reporting System (VAERS) and electronic data available
from the Vaccine Safety Datalink, a population-based database
that included over 400,000 persons who received H1N1
vaccinations. The analysis covered the period of October 1 to
November 24, 2009, during which approximately 11.3 million
doses of the live attenuated influenza vaccine were distributed, and
showed no concerning safety signals (i.e., new, unexpected, or rare
adverse events) and no increased occurrence of monitored
conditions, including Guillain-Barre ´ syndrome.
The seroconversion rates after H1N1 LAIV vaccination
observed in these studies are consistent with those previously
reported from clinical trials conducted with MedImmune’s
seasonal trivalent LAIV [22,24,25,29–34]. A general trend
observed in trivalent LAIV studies is that adults demonstrate
limited HAI responses to LAIV whereas young children,
particularly those without pre-existing antibodies, can exhibit
higher rates of seroconversion in response to vaccination. In
Table 2. Immunogenicity Data for Children 2–17 years.
Baseline seronegative All recipients Children aged 2–9 years
Day 0
n=226,
58*
Day 15
n=112,
28*
Day 29
n=114,
30*
Day 57
n=221,
56*
Day 0
n=255,
64*
Day 15
n=129,
32*
Day 29
n=126,
32*
Day 57
n=250,
62*
Day 0
n=144,
30*
Day 15
n=71,
16*
Day 29
n=73,
14*
Day 57
n=143,
30
GMT
Vaccine 2.03 2.53 2.65 6.05 2.81 3.55 3.53 7.61 2.48 3.15 3.42 6.20
Placebo 2.01 2.21 2.35 3.08 2.50 2.89 2.71 3.70 2.64 3.08 2.32 3.10
Seroconversion rate, %
Vaccine NA 8.9 11.4 34.8 NA 7.8 11.1 32.0 NA 8.5 15.1 28.0
Placebo NA 7.1 6.7 16.1 NA 6.3 6.3 14.5 NA 0 0 6.7
GMT $32, n (%)
Vaccine 42 (19.0) 66 (26.4) 33 (23.1)
Placebo 4 (7.1) 6 (9.7) 2 (6.7)
Rate difference, % (95% CI) 11.9
(11.3, 19.6)
16.7
(5.9, 25.2)
16.4
(0.7, 26.6)
GMT=geometric mean titer; NA=not applicable.
*All n’s are presented as vaccine, placebo.
doi:10.1371/journal.pone.0013755.t002
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have previously been reported following a single dose of LAIV
[29,35], while in children responses after 2 doses of LAIV have
been more variable, ranging from 33% to .90% in seronegative
children and from 22% to approximately 90% in all children
regardless of baseline serostatus [22,24,25,29–34]. The serore-
sponse rates observed in placebo recipients in both studies is likely
attributable to 2009 H1N1 infections occurring in the U.S. during
the period in which these studies were conducted.
The measurement of serum HAI responses following adminis-
tration of LAIV represents a biologically-relevant strain-specific
functional immune response. Serum HAI responses are a useful
biomarker to assess comparability of immune responses and have
enabled previous assessments of formulation bridging, manufac-
turing and lot consistency, as well as concomitant administration
of seasonal LAIV with other live virus vaccines. However for
LAIV, HAI titers are not well correlated with protection against
influenza-like illness since studies have shown vaccine efficacy in
the absence of high rates of serum HAI antibody response [35,36].
In the 6 placebo-controlled pediatric efficacy studies that have
been conducted with LAIV [37], the seroresponse rate for all
subjects for A/H1N1 strains has ranged from 28% to 60%. In five
of these studies clinically significant efficacy was demonstrated
against circulating H1N1 strains matched to the vaccine (ranging
from 81% to 100%) while in the sixth study A/H1N1 strains did
not circulate in the community which precluded an estimate of
efficacy. Similarly, in a study of adults immunized with LAIV and
subsequently challenged with strain-matched wild-type influenza
viruses, the overall HAI seroconversion rate was 20% while
efficacy against laboratory-documented influenza illness was 85%
[35]. While direct information about the efficacy of the live
attenuated 2009 H1N1 vaccine is not yet available, preliminary
data are available from a community-based, open-label, non-
randomized study of a school-located vaccination campaign in
Texas in which 90% of the H1N1 vaccine administered to
children between the ages of 4 and 18 years was LAIV [38]. The
study compared the rates of febrile medically-attended acute
respiratory illness due to influenza in intervention and comparison
cities during the pandemic outbreak in central Texas (September
23 to December 12, 2009) and demonstrated statistically
significant effectiveness in school-aged children 4 to 18 years of
age (relative risk (RR), 0.70; 95% CI: 0.60, 0.81) and also
demonstrated indirect effectiveness in adults 19 to 49 years of age
(RR, 0.78; 95% CI: 0.69, 0.88).
These studies were designed to rapidly provide the US FDA
with sufficient information to guide licensure decisions regarding
MedImmune’s monovalent live attenuated 2009 H1N1 vaccine in
the setting of a widespread H1N1 pandemic; as a result they have
a number of limitations. As mentioned previously, due the
relatively small size of the studies they would not have been able
to detect rare safety signals; however, the very rapid assessment
and release of data from post-marketing surveillance has helped to
address this issue. Additionally, these studies evaluated serum HAI
antibody responses and did not evaluate vaccine replication or
other aspects of the immune response to LAIV. The studies
included HAI testing based on guidance from the US FDA for
consistency with inactivated H1N1 vaccine studies.
These studies demonstrate that 2 doses of 2009 H1N1 LAIV are
safe in healthy children and adults 2 to 49 years of age. Overall,
the frequency of solicited symptoms and AEs were similar between
H1N1 LAIV and placebo recipients, and most were mild to
moderate in severity. While serum immune responses measured by
HAI antibodies are are modest compared to levels achieved by
inactivated vaccines, levels of these antibodies have not been
shown to correlate well with protection against influenza for
LAIV. Antibody levels seen in these studies are consistent
with those reported in other clinical studies of LAIV in which
clinically significant protection against influenza illness has been
demonstrated.
Supporting Information
Figure S1 Solicited Symptoms in (A) Children and (B) Adults
Through Day 15 Postvaccination with Dose 1.
Found at: doi:10.1371/journal.pone.0013755.s001 (0.06 MB
PDF)
Figure S2 Solicited Symptoms in (A) Children and (B) Adults
Through Day 15 Postvaccination with Dose 2.
Table 3. Immunogenicity Data for Adults.
Baseline seronegative All recipients
Day 0
n=200, 45*
Day 15
n=101, 26*
Day 29
n=99, 19*
Day 57
n=189, 42*
Day 0
n=235, 59*
Day 15
n=120, 30*
Day 29
n=115, 29*
Day 57
n=222, 54*
GMT
Vaccine 2.15 2.42 2.57 3.65 3.00 3.46 3.44 4.86
Placebo 2.09 2.00 2.31 2.48 3.64 2.64 4.96 3.90
Seroconversion rate,%
Vaccine NA 3.0 7.1 16.9 NA 2.5 6.1 14.9
Placebo NA 0.0 0.0 7.1 NA 0.0 0.0 5.6
GMT $32, n (%)
Vaccine 14 (7.4) 30 (13.5)
Placebo 1 (2.4) 6 (11.1)
Rate difference,
% , (95% CI)
5.0
(–4.9, 10.7)
2.4
(–9.3, 10.8)
GMFR=geometric mean fold rise; GMT=geometric mean titer; NA=not applicable.
*All n’s are presented as vaccine, placebo.
doi:10.1371/journal.pone.0013755.t003
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